A retinal-based AI diagnostic solution for glaucoma, cataracts, and other retinal diseases.
Reti-eye independently checks your retinal photographs and provides decision support on whether to refer to an ophthalmologist
High Accuracy in detecting eye disease
Our algorithms are extensively trained with high-quality data and validated rigorously by leading medical experts. We ensure a minimum of 96% accuracy, even exceeding human performance.
Immediate results at the point of care
We autonomously detect signs of disease and give you a report in less than a minute on-site to provide a decision on needs before visiting an eye specialist.
Fully automated diagnosis
Retinal diseases – diabetic retinopathy, macular degeneration, epiretinal membranes, etc.
Opacities of the optical media – cataracts, vitreous opacity, vitreous hemorrhage
Glaucoma – glaucomatous optic disc, Retinal Nerve Fiber Layer defect, disc hemorrhage
Detection of referable eye diseases
Reti-Eye automatically detects referable eye diseases including retinal abnormality, glaucoma, and media opacity issues by taking a single retina photo. Reti-Eye recommends patients seek an opthalmologist’s consultation for clinical diagnosis if issues are found.
Common irreversible eye diseases
The leading causes of blindness and low vision are primarily age-related eye diseases such as age-related macular degeneration, cataract, diabetic retinopathy, and glaucoma.
Glaucoma is a disease that damages the optic nerve in your eyes. Often known as a silent killer, if left untreated, it will lead to permanent vision loss.
Age-related Macular Degeneration
Age-related Macular Degeneration (AMD) is an age-related deterioration of the vision focal point in your eye. AMD can interfere with daily activities such as driving, reading, and writing.
A cataract is a clouding of the lens in the eye that affect vision. Most cataracts are related to aging and are commonly found among older people.
Diabetic Retinopathy (DR) is a common complication of diabetes leading to severe and permanent blindness. As DR is asymptomatic in the early stages, patients may not notice any change in their vision at first.
Save costs through early detection and management of glaucoma, cataracts, and other retinal diseases.
Screen for eye diseases in all healthcare settings before your long-awaited appointment with an ophthalmologist.
Know your risk for referable eye disease in time without unnecessary referrals. The earliest possible detection allows the earliest possible treatment.
How Reti-Eye works
Take 1 retinal photograph per eye using a fundus camera by optometrists or technicians
Submit images to the cloud for analysis and type patient information
Automatically analyze for signs of eye disease risk within a minute
Generate personalized health screening results and download the report
Refer to specialists for further follow-up or suggest lifestyle changes and regular check-ups
Get your result within a minute
Approval of Medical device & Commercial use
Approved in 8 territories
Mediwhale is the only company that obtained approval for eye disease risk assessment using retinal images as a biomarker. Reti-Eye has approvals for the medical device in the EU and Asia and is under FDA clearance in the US.
DrNoon is an approved product name of Reti-Eye & Reti-CVD in some territories.
Multi-categorical deep learning neural network to classify retinal images: A pilot study employing small database
Deep learning emerges as a powerful tool for analyzing medical images. Retinal disease detection by using computer-aided diagnosis from fundus image has emerged as a new method.
Deep learning is effective for classifying non-referable versus referable eye conditions using fundus photographs
Investigative Ophthalmology & Visual Science